To clarify the action mechanism of anti-PCSK9 antibody therapy for acute coronary syndrome
Not Applicable
- Conditions
- acute coronary syndrome
- Registration Number
- JPRN-UMIN000030860
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 126
Inclusion Criteria
Not provided
Exclusion Criteria
significant liver dysfunction(ALT more than 100 U/L), serum creatinine level more than 3 mg/dl, end-stage renal disease, a pregnancy or inability to provide written informed consent, Participants had already had anti-PCSK9 antibody on admission, participants had serious complication of PCI
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse Cardiac and Cerebrovascular Events (all cause death, cardiovascular death, cerebrovascular accident, coronary revascularization etc)
- Secondary Outcome Measures
Name Time Method